2 Healthcare Stocks That Turned $1,000 Into $2,400 (or More)
Turning $1,000 into $2,400 in five years is no easy feat -- it requires a compound annual growth rate (CAGR) of 19.1%. However, both Regeneron (NASDAQ: REGN) and Moderna (NASDAQ: MRNA) have been able to pull that off (and then some) in the past half decade. Naturally, that doesn't automatically make these biotech stocks worth buying. Past performance isn't a guarantee of future success.
Can Regeneron and Moderna deliver similar returns in the next five years? Let's dig in and find out.
Source Fool.com
Regeneron Pharmaceuticals Inc. Aktie
992,20 €
-1,96 %
Regeneron Pharmaceuticals Inc. ist ein klarer Community-Favorit mit mehr Buy- als Sell-Einschätzungen.
Ein positives Kurspotenzial für Regeneron Pharmaceuticals Inc. ist gegeben, mit einem Kursziel von 1040 € über dem aktuellen Kurs von 992.2 €.
